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Purpose. To assess the safety profile of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD)
in routine clinical practice. Methods. This 2-year, multicentre, observational study was conducted to capture real-world early
practice and outcomes across Europe, shortly after European licensing of ranibizumab for nAMD. Being observational in nature,
the study did not impose diagnostic/therapeutic interventions/visit schedule. Patients were to be treated as per the EU summary of
product characteristics (SmPC) in effect during the study. Key outcome measures were incidence of selected adverse events (AEs),
treatment exposure, bilateral treatment, compliance to the EU SmPC, and best-corrected visual acuity (BCVA) over 2 years.Results.
755 of 770 patients received treatment. Ranibizumab was generally well tolerated with low incidence of selected AEs (0%–1.9%).
Patients received 6.2 (mean) injections and 133 patients received bilateral treatment over 2 years. Protocol deviation to treatment
compliance was reported in majority of patients. The observed decline in mean BCVA (Month 12, +1.5; Month 24, –1.3 letters)
may be associated with undertreatment as suggested by BCVA subgroup analysis. Conclusion. The EPICOHORT study conducted
in routine clinical practice reinforces the well-established safety profile of ranibizumab in nAMD. In early European practice it
appeared that the nAMD patients were undertreated.
1. Introduction
Ranibizumab (Lucentis, Novartis PharmaAG, Basel, Switzer-
land, and Genentech Inc., South San Francisco, CA, USA) is
a humanised monoclonal antibody Fab fragment, specifically
designed for ocular use, that binds with high affinity to
and inhibits multiple biologically active isoforms of vascular
endothelial growth factor A (VEGF-A; [1]). Ranibizumabwas
approved for the treatment of neovascular age-related macu-
lar degeneration (nAMD) in many countries worldwide as of
2006.The efficacy and safety profile of ranibizumab in nAMD
is well established based on the results of several randomised
clinical trials (RCTs) conducted on approximately ≥7500
patients [2–11]. The prospective extension studies, SECURE
and HORIZON, have also established the long-term safety
profile of ranibizumab 0.5mg over a follow-up period of 24
months [12, 13].
RCTs are by nature conducted in a controlled setting,
have stringent inclusion and exclusion criteria, and mostly
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include treatment-näıve patients. Consequently, it is of inter-
est to translate RCT results into real-world clinical practice.
Therefore, there is a need for observational studies conducted
on a large and diverse patient population to further evaluate
the potential risks of serious but infrequent adverse events
(AEs) and the efficacy of ranibizumab in a real-world setting.
Evidence to establish the safety profile of ranibizumab in
routine clinical practice is growing with small clinical studies
as well as with the large on-going LUMINOUS study [14–20].
The EPICOHORT study was designed, as part of the
on-going postmarketing commitment of Novartis Pharma
AG (Basel, Switzerland) to the European Medicines Agency
(EMA).TheEPICOHORTwas a postapproval study designed
to assess the safety profile, treatment patterns, and efficacy
of ranibizumab in real-life clinical setting/routine clinical
practice. This 2-year study was conducted between Septem-
ber 30, 2008, and November 15, 2011, in a cohort of Euro-
pean ophthalmology clinics that had, by EMA request, not
previously participated in clinical studies with ranibizumab.
Ranibizumab treatment was based on investigator’s judgment
and guided by EU SmPC in effect during the time of study
limited by their daily practice. More specifically, up until
September 19, 2011, the EU SmPC retreatment criteria were
based on a loss of visual acuity (VA). All clinical assessments
were performed at the discretion of the study investigator as
part of his/her current practice to reflect the real-life practice
in EU ophthalmology clinics. This paper reports the findings
from this 2-year, phase IV, multicentre, observational study
conducted in a real-world setting.
2. Materials and Methods
2.1. Study Design. This was a 2-year, multicentre, phase IV,
open-label, observational, noncomparative cohort study on
patients with nAMD from 54 European clinical centres that
had not participated in clinical studies with ranibizumab.
The study was conducted in accordance with the Interna-
tional Conference on Harmonisation Tripartite Guidelines
for Good Clinical Practice, with applicable local regulations
and ethical principles laid down in the Declaration of
Helsinki. The study protocol was reviewed and approved by
the Independent Ethics Committee or Institutional Review
Board of each centre.Written informed consent was obtained
from each participating patient before enrolment.
2.2. Patients. The outpatient study population consisted of
patients diagnosed with choroidal neovascularisation (CNV)
secondary to AMD. The patients were to be treated with
ranibizumab at study entry.
2.3. Treatment. Due to the observational nature of the study,
the study protocol did not impose diagnostic/therapeutic
interventions like optical coherence tomography (OCT)
assessments or a visit schedule. Patients were treated with the
commercially available intravitreal injections of ranibizumab
0.5mg (Lucentis) as per the investigators’ judgement and
guided by the current EU SmPC in effect during the time
of the study, During the study period (September 30, 2008,
to November 15, 2011), the SmPC was updated nine times
and all SmPC versions before September 2011 had the same
retreatment criteria. The treatment criteria were to treat with
ranibizumab 0.5mg when patients experienced a loss of ≥5
letters in VA (Early Treatment Diabetic Retinopathy Study
(ETDRS) letters or Snellen equivalent). Data were recorded
by the investigator at each patient visit.
2.4. Study Objectives. The key objectives of the study were to
describe the characteristics of nAMD patients treated with
ranibizumab in European clinics; incidence of bilateral use of
ranibizumab; compliance to the EU SmPC in effect during
the time of the study; incidence of the following selected
adverse events (AEs): endophthalmitis, retinal detachment,
vitreous haemorrhage, retinal tear, traumatic cataract, uveitis,
and elevated intraocular pressure (IOP); and best-corrected
visual acuity (BCVA) as a clinical efficacy measure in the
study population.
2.5. Assessments and End Points
2.5.1. Patient Demographics and Other Baseline Characteris-
tics. Demographic patient data including age, gender, race,
and ethnicity were collected at the study entry. Details on
medical history and current medical conditions (including
ocular-related history/conditions), on-going medications,
and significant nondrug therapies were also recorded, if
provided by the patient. BCVA was assessed at study entry
or if not done a prior VA value closest to the study entry was
recorded. However, during the analysis, patients who did not
have the baseline VA were excluded from the analyses.
2.5.2. Treatment Exposure. The number of ranibizumab
injections and the bilateral use of ranibizumab were
recorded over the 2-year treatment period. Bilateral use
of ranibizumab was assessed by (i) proportion of patients
receiving ranibizumab treatment in both eyes at any time
during the study and (ii) proportion of patients with bilateral
treatment within 28 days and on the same day.
2.5.3. Compliance to the Current EU SmPC. Data on com-
pliance to the EU SmPC in terms of treatment dose, use of
antimicrobial eye drops, treatment despite contraindications,
interval between two treatments, and compliance to retreat-
ment criteria, as well as reported reasons for noncompliance,
were collected at every patient visit.
2.5.4. Safety Assessment. Safety profile was assessed by
recording the incidence of AEs and serious adverse events
(SAEs) over the 2-year assessment period. AEs were assessed
by the investigator by nondirective questioning of patients at
each visit (i.e., asking questions without including symptoms,
so as not to influence the outcomes), voluntary reports by
the patients during or between visits or through physical
examination. Incidence of the selected AEs (endophthalmi-
tis, retinal detachment, vitreous haemorrhage, retinal tear,
traumatic cataract, uveitis, and elevated IOP) was assessed
based on the records provided by the study investigator.
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Study completion: n (%)
Month 12: 695 (90.3)
Month 24: 545 (70.8)
Enrolled patients: N = 770
Ranibizumab 0.5mg
N = 755
225 (29.2%) patients discontinued the study
Reasons for study discontinuation, n (%)
∙ Adverse event(s): 2 (0.3)
∙ Unsatisfactory therapeutic effect: 11 (1.4)
∙ Patient’s condition no longer requires study
drug: 24 (3.1)
∙ Patient withdrew consent: 23 (3.0)
∙ Lost to follow-up: 75 (9.7)
∙ Administrative problems: 58 (7.5)
∙
∙ Protocol deviation: 9 (1.2)
Death∗ : 23 (3.0)
Patients who did not receive ranibizumab: n = 15
Figure 1: Patient disposition (all enrolled patients). ∗Except for
one, none of the deaths were suspected to be related to the study
treatment.
The incidence was calculated on a per-patient basis over 2
years. In addition, the incidence of the selected AEs was also
calculated on per-injection and per-patient-year basis for a
period of 2 years.
2.5.5. Best-Corrected Visual Acuity. BCVAwas assessed using
either the Snellen or ETDRS charts. For the analysis, the
Snellen equivalentwas converted to anETDRS score.The effi-
cacy end point was mean change in BCVA letter score from
baseline to Month 24. Other efficacy end points included
proportion of patients with BCVA letter score gain of ≥15
ETDRS letters and loss of <15 ETDRS letters from baseline
to Month 24. An exploratory subgroup analysis on efficacy
was performed based on the number and timing of initial
injections.The subgroups data reported here were descriptive
only and no statistical analysis was intended. The categories
assessed were based on the number of injections within
90 days from baseline (<3, ≥3 injections) and number of
injections within 90 days from baseline and overall injections
(≥3 injections within 90 days from baseline but <10 injections
overall and ≥3 injections within 90 days from baseline and
≥10 injections overall).
2.6. Statistical Analysis. TheEPICOHORT study focused pri-
marily on the safety profile of ranibizumab and no statistical
hypothesis testing was intended. All analyses were performed
on the safety set, which included patients treated with at
least one dose of ranibizumab and who had at least one
safety assessment after the first treatment. All analyses were
conducted on the safety set except for patient disposition,
which was based on the enrolled set (patients who entered
into the study and for whom data were recorded). Patient
characteristics were summarised using descriptive statistics.
All AEs were reported based on the Medical Dictionary for
Regulatory Activities (MedDRA) system organ classes and
preferred terms. The incidence of AEs (ocular/nonocular)
was listed based on the seriousness and relationship to the
study drug/procedure. The incidence of selected AEs was
calculated based on the proportion of patients with at least
one AE over 2 years. The corresponding 95% (Clopper-
Pearson) confidence intervals for the incidence rate were
presented on a per-patient basis. Ocular and nonocular safety
assessments were carried out including assessments of the
second-treated eye (as applicable). The first-treated eye was
the eye that received the first dose of treatment according to
the date and time of treatment during the study. The other
eye was considered as a fellow eye (nontreated) until the
date it was treated during the study, at which it became the
second-treated eye. In this paper, wemainly report the results
for the first-treated eye. Compliance to the EU SmPC was
summarised using descriptive statistics. All efficacy analyses
were performed on the observed data of the safety set. In
addition, the analysis was repeated using the last observation
carried forward (LOCF) results (i.e., carrying forward the last
nonmissing postbaseline results).
3. Results
3.1. Patient Disposition and Baseline Characteristics. A total
of 770 patients were enrolled in this study and the gross
enrolment happened within 4 months of the study. Out of
770 enrolled patients, 755 patients received treatment. Fifteen
patients did not receive any ranibizumab treatment and
therefore were not included in the safety analysis. Overall,
695 (90.3%) patients and 545 (70.8%) patients completed the
study in years 1 and 2, respectively. The premature study
discontinuation was mainly due to “administrative reasons”
(58 [7.5%]) or patients “lost to follow-up” (75 [9.7%]). Two
patients (0.3%) discontinued the study due to an AE and
11 patients (1.4%) discontinued because of unsatisfactory
therapeutic effect. The proportion of patients who discon-
tinued the study and the reasons for discontinuation are
shown in Figure 1. The mean (±SD) age of patients was
76.3 (±8.7) years and the majority of them were ≥65 years
and Caucasian (99.2%). The mean (±SD) BCVA of the first-
treated eye and the nontreated eye at baseline was 52.8
(±20.3) and 57.2 (±20.2) letters, respectively. Prior ocular
medication was voluntarily reported in 270 (35.8%) patients
with ranibizumab being themost frequently usedmedication
in 251 (33.2%) patients.
3.2. Treatment Exposure and Compliance
3.2.1. Ranibizumab Injections. A mean of 6.2 ranibizumab
injections was administered during the study (first year: 4.4;
second year: 1.8) over 2 years (Table 1).
3.2.2. Bilateral Treatment. A mean (±SD) of 4.9 (±3.5) injec-
tions was administered in the second-treated eye over 2 years.
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Number of injections in the
first-treated eye
Year 1 3306
Mean (SD) 4.4 (2.3)
Overall (24 months) 4711
Mean (SD) 6.2 (4.3)
Patients with bilateral treatment over
24 months, 𝑛 (%) 133 (17.6)
Patients with bilateral treatment within
28 days, 𝑛 (%) 87 (11.5)
Safety set was defined as all those patients who were treated with at least one
dose of ranibizumab and who had at least one safety assessment after study
entry and no protocol deviations that warranted exclusion.
The total number of injections is number of injections received since the start
of the study in the specific eye.
Patients with bilateral treatment represent the patients who received treat-
ment in both eyes.
SD: standard deviation.
Overall, 133 (17.6%) patients received bilateral treatment dur-
ing the study, of which 87 (11.5%) patients received bilateral
treatment within 28 days and 19 (2.5%) patients received
bilateral treatment on the same day (Table 1).
3.2.3. Compliance to the Current EU SmPC. Patients with
at least one protocol deviation were recorded during the
study. The majority of protocol deviations were related either
to patients not self-administering antimicrobial eye drops
before or after the injection (360 [47.7%]) or to minor proce-
dural deviations (379 [50.2%]). These procedural deviations
were mainly related to the patient reconsent process after
the informed consent amendment and to the delay of SAE
reporting (Table 2). Further analysis revealed that more than
10,000 of 13,483 evaluations performed for treatment need
were in accordance with the EU SmPC requirement, and
approximately half of a total of 5,368 treatments given were
compliant with the EU SmPC. The reasons for noncompli-
ance were not systematically recorded. The median of the
minimum duration between 2 consecutive visits was 29 days.
3.3. Safety
3.3.1. Selected AEs. The overall incidence of the selected
AEs in the first-treated eye is shown in Table 3. Over the
2-year study period, no cases of retinal detachment or
traumatic cataract were reported, whereas endophthalmitis
and uveitis were reported in one (0.1%) patient each in
the first-treated eye. Following bilateral treatment (second-
treated eye), vitreous haemorrhage and elevated IOP were
reported in one (0.1%) patient each. However, no cases of
endophthalmitis, retinal detachment, retinal tears, traumatic
cataract, or uveitis were reported in patients with second-
treated eye.The selected AEs analysed based on per injection,
per patient-year, and per treated eye are presented in Table 4.
3.3.2. Serious Adverse Events. Overall, ocular SAEs (first-
treated eye) were reported in 12 (1.6%) patients (Table 5).
Except for retinal haemorrhage (4 patients, 0.5%) and retinal
pigment epithelial (RPE) tear (2 patients, 0.3%), all SAEswere
reported in one patient each. Ocular SAEs suspected to be
related to the study drug and/or treatment procedure were
reported in 6 (0.8%) patients. Ocular SAEs suspected to be
related to the study drug were reported in 4 (0.5%) patients.
Endophthalmitis and retinal haemorrhage were reported in 1
(0.1%) patient each, both suspected by the investigator to be
related to the study drug and treatment procedure.
Nonocular SAEs were reported in 89 (11.8%) patients.
Most frequent nonocular SAEs were cerebrovascular acci-
dent, chronic obstructive pulmonary disease, and hyperten-
sion, each reported in 5 (0.7%) patients (Table 5). Nonocular
SAEs suspected to be related to the study drug and/or
treatment procedure were reported in 6 (0.8%) patients.
Nonocular SAEs suspected to be related to study drug were
reported in 5 (0.7%) patients.
There were 23 (3%) deaths reported during the study.
Except for one, none of the deaths were suspected to be
related to the study treatment. For this one patient, who had
a medical history of hypertension and myocardial ischaemia,
the cause of death was stroke and the event was suspected to
be related to the study drug and treatment procedure, by the
investigator.
3.3.3. Adverse Events. Ocular AEs (first-treated eye) were
reported in 255 (33.8%) patients. The most frequently
reported ocular AEs were conjunctival haemorrhage (58
[7.7%]), eye irritation (25 [3.3%]), and cataract (24 [3.2%];
Table 6). RPE tear (7 [0.9%]) was the most frequently
reported ocular AE suspected by the investigator to be
related to the study drug. Nonocular AEs were reported in
236 (31.3%) patients (Table 6). The most frequently reported
nonocular AEs were hypertension (19 [2.5%]) and influenza
(17 [2.3%]). Hypertension (4 [0.5%]) was the most frequent
nonocular AE suspected by the investigator to be related to
the study drug.
3.4. Efficacy
3.4.1. Best-Corrected Visual Acuity. Ranibizumab treatment
led to BCVA (mean [±SE]) improvements at Month 3 (+4.5
[0.52] letters) and then to a continuous decline in BCVA
until Month 24. At Months 12 and 24, the mean change
(±SE) in BCVA from baseline was +1.5 (0.61) letters and −1.3
(0.72) letters, respectively (Figure 2(a)). A subgroup analysis
onBCVAbased on the number and timing of initial injections
demonstrated that patients receiving <3 injections within the
first 90 days (𝑛 = 306) lost 3.7 letters, whereas patients
receiving ≥3 injections within the first 90 days (𝑛 = 449)
gained 0.3 letters at Month 24. In addition, patients who
received ≥3 injections within 90 days but <10 injections
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At least one protocol deviation∗, 𝑛 (%)
Injection of more than 0.5mg (overdose) 1 (0.1)
Minor procedural deviations without obvious impact on the safety of the patient 379 (50.2)
No single use of vial (multiple injections) 40 (5.3)
Patient did not self-administer antimicrobial drops (4 times daily for 3 days) before or after the injection 360 (47.7)
Patient has no CNV secondary to AMD 2 (0.3)
Overall instances of each protocol deviation†, 𝑛/𝑁
Injection of more than 0.5mg (overdose) 1/1
Minor procedural deviations without obvious impact on the safety of the patient 575/379
No single use of vial (multiple injections) 40/40
Patient did not self-administer antimicrobial drops (4 times daily for 3 days) before or after the injection 2242/360
Patient has no CNV secondary to AMD 2/2
∗At least one section only counts a protocol deviation once per patient.
†Overall instance section reports all instances of each protocol deviation (𝑛) and the total number of patients involved in those instances (𝑁).
AMD: age-related macular degeneration; CNV: choroidal neovascularisation.








Total 21 (2.8) (1.7, 4.2)
Intraocular pressure
increased 14 (1.9) (1.0, 3.1)
Vitreous haemorrhage 3 (0.4) (0.1, 1.2)
Retinal tears 2 (0.3) (0.0, 1.0)
Endophthalmitis 1 (0.1) (0.0, 0.7)
Uveitis 1 (0.1) (0.0, 0.7)
Cataract traumatic 0 (0.0, 0.5)
Retinal detachment 0 (0.0, 0.5)
Safety set was defined as all those patients who were treated with at least one
dose of ranibizumab and who had at least one safety assessment after study
entry and no protocol deviations that warranted exclusion.
∗Exact Binomial (Clopper-Pearson).
Special event-preferred terms are presented in the descending order of
frequency.
AEs occurring only during the safety observation period are included.
A patient with multiple occurrences of an AE is counted only once in the
preferred term category.
AE: adverse event; CI: confidence interval; LL: lower limit; UL: upper limit.
overall (𝑛 = 349) lost 0.3 letters, while patients who received
≥3 injections within 90 days and ≥10 injections overall (𝑛 =
100) gained 2.1 letters at Month 24 (Figure 2(b)).
4. Discussion
The EPICOHORT study conducted in a routine clinical
practice in Europe demonstrated that ranibizumab 0.5mg
therapy was well tolerated in patients with nAMD, with no
new ocular or nonocular safety findings observed over the 2-
year study period.The broad involvement of European clinics
across 54 centres and an observational design of the study
(i.e., no treatment protocol) reflect the real-life practice in
European ophthalmology clinics.
In the EPICOHORT study, the incidence of selected AEs
was low (0%–1.9%) and similar to that observed in RCTs with
pro re nata (PRN) regimen in nAMD patients [12, 13, 21–23].
This indicates that the safety profile of ranibizumab in clinical
practice is not substantially different from what was reported
in RCTs with PRN regimen. However, these results need to be
interpreted with caution due to differences in comorbidities,
study design, and treatment criteria used in these trials.
Of a total of 4711 ranibizumab injections adminis-
tered during the study, only one case of endophthalmitis
(0.0002/injection) was reported. In this case, the patient
received 40 intravitreal ranibizumab injections prior to the
event (20 in the first-treated eye and 20 in the second-treated
eye); the first-treated eye with endophthalmitis responded to
ranibizumab treatment and the patient completed the study
with a gain of 3 letters in that eye. Although 19 patients
received bilateral treatment on the same day, no cases of
endophthalmitis were reported in these patients. In addition,
there were no unexpected safety findings in both the bilateral
treatment categories whether administered on the same day
(𝑛 = 19) or within 28 days (𝑛 = 87). Overall, the incidence
of endophthalmitis and other selected AEs observed in this
study is comparable to that observed in RCTs conducted in
patients with nAMD. Additionally, the incidence of selected
AEs observed in this study was also comparable to those
observed in the LUMINOUS retrospective study, which was
also conducted in a real-life setting [17–20].
The incidence of ocular and nonocular AEs and SAEs
over the 2-year study period was low and consistent with
6 Journal of Ophthalmology
3 6 9 12 15 18 21 24
Months







































12 15 18 21 24
Months
270 255 260 262 262 262 262 262 264<3 in 90 days
410 403 407 408 409 409 409 409 409≥3 in 90 days
316 310 314 315 315 315 315 315 315≥3 in 90 days 
but <10 overall
94 93 93 93 94 94 94 94 94≥3 in 90 days 
and ≥10 overall
<3 injections within 90 days (n = 306)
≥3 injections within 90 days (n = 449)
≥3 injections within 90 days but <10 injections overall (n = 349)




































Figure 2: (a) Overall mean change in BCVA over time in the first-treated eye and (b) mean change in BCVA overtime based on the number
of injections in the first-treated eye (safety set, LOCF). Safety set was defined as all those patients who were treated with at least one dose
of ranibizumab and who had at least one safety assessment after study entry and no protocol deviations that warranted exclusion. Baseline
VA results were recorded for 680 patients. Month 24 results were evaluated for 673 patients using the LOCF approach. BCVA: best-corrected
visual acuity; LOCF: last observation carried forward.
those observed in RCTs using PRN regimen in patients with
nAMD [12, 13, 21–23]. Of the 23 (3.0%) deaths reported
during the study, except for one, none of the other deaths
were suspected to be related to the study drug or treatment
procedure by the investigator. For this one patient, the cause
of death was stroke and the patient had a medical history of
hypertension and myocardial ischemia. Overall, there were
no new ocular and nonocular safety findings observed in the
EPICOHORT study, and the safety profilewas consistent with
the well-established safety profile of ranibizumab in nAMD.
Over the 2-year study period, at least one protocol
deviation was reported in majority of the patients. It may be
inferred that due to the observational nature of this study
and especially since the clinics chosen were participating for
the first time in a ranibizumab clinical trial, the standard
procedure of ocular injections (as per the EU label) may not
be consistently followed.This is supported by the observation
that the majority of protocol deviations were due to omission
of antimicrobial eye drops before or after injection (47.7%).
Despite this noncompliance to the EU SmPC and protocol
deviations, the overall incidence of endophthalmitis (0.1%;
0.0002/injection) was low and within the range as observed
in RCTs with PRN regimen [12, 13, 21–23]. In addition, only
two patients prematurely discontinued the study due to an
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Table 4: Selected AEs over 2 years: per injection, per patient-year






Total number of injections 4711
Intraocular pressure increased 40 (0.0085)
Vitreous haemorrhage 3 (0.0006)






Total number of years 1361
Intraocular pressure increased 40 (0.0294)
Vitreous haemorrhage 3 (0.0022)





AEs per treated eye‡
Total number of treated eyes 888
Intraocular pressure increased 41 (0.0462)
Vitreous haemorrhage 5 (0.0056)





Safety set was defined as all those patients who were treated with at least one
dose of ranibizumab and who had at least one safety assessment after study
entry and no protocol deviations that warranted exclusion.
∗Number of AEs (rate per injection), where rate per injection is calculated
as the number of events/total number of injections.
†Number of AEs (rate per year), where rate per patient-year of safety
observation is calculated as the number of events/total number of patient-
years.
‡Number of AEs (rate per eye), where rate per treated eye is calculated as the
number of events/total number of treated eyes.
Preferred terms are presented in the descending order of frequency.
All occurrences of the AE during the safety observation period are included
in the AE category (including multiple occurrences per patient).
AE: adverse event.
AE, with the reasons being mainly “administrative reasons”
(7.5%) or patients “lost to follow-up” (9.7%).
In the current study, a mean BCVA gain of +4.5 letters
from baseline was observed at Month 3 followed by a decline
over 24 months. A subgroup analysis of BCVA improvement
based on the number of injections showed that more than
1/3 (𝑛 = 306) of the overall study population received <3
injections within 90 days, although the EU label in effect
Table 5: Patients with ocular SAEs and frequent nonocular SAEs








Total 12 (1.6) (0.8, 2.8)
Retinal haemorrhage 4 (0.5) (0.1, 1.4)
Retinal pigment
epithelial tear 2 (0.3) (0.0, 1.0)
Angle closure
glaucoma 1 (0.1) (0.0, 0.7)
Endophthalmitis 1 (0.1) (0.0, 0.7)
Glaucoma 1 (0.1) (0.0, 0.7)
Intraocular pressure
increased 1 (0.1) (0.0, 0.7)
Macular hole 1 (0.1) (0.0, 0.7)
Open angle glaucoma 1 (0.1) (0.0, 0.7)
Optic neuritis 1 (0.1) (0.0, 0.7)
Visual acuity reduced 1 (0.1) (0.0, 0.7)
Vitreous haemorrhage 1 (0.1)† (0.0, 0.7)
Nonocular SAEs
Total 89 (11.8)‡ (9.6, 14.3)
Cerebrovascular
accident 5 (0.7) (0.2, 1.5)
Chronic obstructive
pulmonary disease 5 (0.7) (0.2, 1.5)
Hypertension 5 (0.7) (0.2, 1.5)
Pneumonia 4 (0.5) (0.1, 1.4)
Cardiac failure 3 (0.4) (0.1, 1.2)
Colon cancer 3 (0.4) (0.1, 1.2)
Depression 3 (0.4) (0.1, 1.2)
Femur fracture 3 (0.4) (0.1, 1.2)
Safety set was defined as all those patients who were treated with at least one
dose of ranibizumab and who had at least one safety assessment after study
entry and no protocol deviations that warranted exclusion.
∗Exact Binomial (Clopper-Pearson).
†Patient discontinued the treatment due to SAE.
‡17 patients discontinued the treatment due to nonocular SAE.
SAEs occurring only during the safety observation period are included.
Preferred terms are presented in the descending order of frequency.
A patient with multiple occurrences of an AE is counted only once in the
preferred term category.
A patient with multiple AEs is counted only once in the total row.
AE: adverse event; CI: confidence interval; LL: lower limit; SAE: serious
adverse event; UL: upper limit.
during the time of study recommended three initial monthly
loading injections.This may be because over 1/3 of the overall
population (𝑛 = 270 [35.8%]) was not naı̈ve to nAMD
treatment and had been pretreated, mainly with ranibizumab
(𝑛 = 251 [33.2%]). These pretreated patients may not have
required the threemonthly loading injections of ranibizumab
within 3 months of recruitment and were less likely to have
improvements in BCVA than the treatment-näıve patients.
This may explain the lack of mean BCVA improvement in
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Table 6: Patients with frequent (≥1%) ocular and nonocular AEs








Total 255 (33.8) (30.4, 37.3)
Conjunctival
haemorrhage 58 (7.7) (5.9, 9.8)
Eye irritation 25 (3.3) (2.2, 4.8)
Cataract 24 (3.2) (2.0, 4.7)
Conjunctivitis 22 (2.9) (1.8, 4.4)
Eye pain 21 (2.8) (1.7, 4.2)
Vitreous floaters 18 (2.4) (1.4, 3.7)
Retinal haemorrhage 17 (2.3) (1.3, 3.6)
Intraocular pressure
increased 14 (1.9) (1.0, 3.1)
Ocular hypertension 14 (1.9) (1.0, 3.1)
Conjunctivitis allergic 10 (1.3) (0.6, 2.4)
Injection site discharge 10 (1.3) (0.6, 2.4)
Retinal pigment
epithelial tear 10 (1.3) (0.6, 2.4)
Blepharitis 9 (1.2) (0.5, 2.3)
Glaucoma 8 (1.1) (0.5, 2.1)
Posterior capsule
opacification 8 (1.1) (0.5, 2.1)
Nonocular AEs
Total 236 (31.3) (28.0, 34.7)
Hypertension 19 (2.5) (1.5, 3.9)
Influenza 17 (2.3) (1.3, 3.6)
Diabetes mellitus 10 (1.3) (0.6, 2.4)
Nasopharyngitis 10 (1.3) (0.6, 2.4)
Urinary tract infection 10 (1.3) (0.6, 2.4)
Hypercholesterolemia 9 (1.2) (0.5, 2.3)
Safety set was defined as all those patients who were treated with at least one
dose of ranibizumab and who had at least one safety assessment after study
entry and no protocol deviations that warranted exclusion.
∗Exact Binomial (Clopper-Pearson).
AEs occurring only during the safety observation period are included.
Preferred terms are presented in the descending order of frequency.
A patient with multiple occurrences of an AE is counted only once in the
preferred term category.
A patient with multiple AEs is counted only once in the total row.
AE: adverse event; CI: confidence interval; LL: lower limit; UL: upper limit.
patients receiving <3 injections within 90 days (𝑛 = 306;
Figure 2(b)). On the other hand, patients who received ≥3
injections within 90 days (𝑛 = 449) of recruitment improved
their BCVA, of which 100 patients who were treated with
≥10 injections over 24 months showed an improvement of 2.1
letters.
Overall, the mean number of injections was low (6.2)
and potentially some patients may have been undertreated
during the study. The possible undertreatment may be due
to the observational nature of the study design (without a
scope for specific retreatment criteria other than that in the
product label, a standard diagnostic/therapeutic intervention
or a visit schedule) and factors related to local practice (e.g.,
reimbursement issues, patient follow-up). Additionally, for a
major part of the study period (i.e., until September 2011)
the patients were treated only if they experienced a loss
of ≥5 letters as per the current EU SmPC at the time of
study. This may have led to retreatment decisions reactive
to loss of VA rather than proactive that aim at detecting
the early signs of disease activity before actual VA loss. In
contrast to this study, a more recent study that has used PRN
dosing regimen using both VA and OCT retreatment criteria
with monthly monitoring showed VA outcomes comparable
to that observed with monthly ranibizumab treatment [23].
Thus, detecting the early signs of anatomical changes and
treating the disease activity promptly before actual VA loss
along with adequate monitoring may help to achieve better
visual gains.
In summary, ranibizumab treatment was generally well
tolerated in patients with CNV secondary to AMD in routine
clinical practice in European clinics that had not previously
participated in clinical trials with ranibizumab.The incidence
of selected AEs was low, and no new ocular or nonocular
safety findingswere observed in this study.Noncompliance to
prior antibiotic application did not seem to have any effect on
the incidence of endophthalmitis. The recommendation for
the patient self-administering antimicrobial drops, four times
daily for 3 days before and after injection, is now removed
in the current EU label (January 2014). Further studies
supporting ranibizumab use in clinical practice are on-
going. The on-going LUMINOUS study (ClinicalTrials.gov
[NCT01318941]), which is successfully enrolling patients
worldwide, will help to provide further evidence on the long-
term safety, effectiveness, treatment patterns, and quality-of-
life outcomes of ranibizumab treatment in routine clinical
practice.
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